arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

CG Oncology, Inc.

CGON

$75.11 ▲ +0.38 (+0.51%) at close

4 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Bullish

auto_awesome

Analytical Summary

CG Oncology, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $5.8B

Dividend Yield —

Revenue Growth 254.7% ↘

Op. Margin —

ROIC -19.9% ↘

FCF / Share $-1.71 ↘

Trailing P/E —

Price / Book 8.1x

FCF Yield —

Debt / Equity 0.00

info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$4.04M

↑ +254.7% —

Net Income Profit after all expenses

$-161.00M

↓ -82.9% —

FCF / Share Free cash flow per share

$-1.71

↓ -35.7% —

Long-Term Debt Long-term obligations

$3.00M

— —

trending_up

Bullish Indicators

Debt to EquityDebt to Equity is in the top quartile (lower is better)

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue Growth YoY (%)	254.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3084%)	458.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5629%)	—	—
EPS Growth YoY (%)	-47.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	91.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-82.9% Weak Weak Year-over-year change in net income	-81.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-35.7% Weak Weak Year-over-year change in free cash flow	88.0% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-19.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	35.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-24.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-27.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-21.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-12.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-180%)	39.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+163%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Debt to Equity (x)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	—	—
Interest Coverage (x)	-1852.17x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-147.47x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-29.49M	$-257.07M	$-8.27M	—
Debt / EBITDA (x)	-0.02x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Revenue per Share (USD)	$0.05	$0.02	$0.05	—
Basic EPS, GAAP (USD)	$-2.08	$-1.41	$-15.65	—
Free Cash Flow per Share (USD)	$-1.71	$-1.26	$-10.55	—
Book Value per Share (USD)	$9.33	$9.63	$-23.57	—
Tangible Book Value per Share (USD)	$9.20	$9.63	$-23.57	—
Basic Weighted Avg Shares (shares)	77.30M	62.50M	4.33M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$728.64M	$732.84M	$179.87M	—
LT Debt (USD)	$3.00M	$0.00	—	—
Total Equity (USD)	$752.60M	$733.38M	$-123.10M	$-77.69M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗
Sales/Revenue/Turnover (USD)	$4.04M	$1.14M	$204.00K	—
Depreciation Expense (USD)	$1.45M	$32.00K	$17.00K	—
Net Income, GAAP (USD)	$-161.00M	$-88.04M	$-48.61M	—
Operating Cash Flow (USD)	$-132.35M	$-78.71M	$-45.68M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

CG Oncology, Inc.

Analytical Summary

4-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare CGON with peers